Novartis announces pelacarsen Lp(a)HORIZON Phase 3 topline: primary endpoint missed
Novartis announced pelacarsen Phase 3 Lp(a)HORIZON topline results. The study did not meet its primary endpoint to reduce the risk of cardiovascular events, a composite including cardiovascular death and non-fatal myo…
Novartis said today the Phase 3 Lp(a)HORIZON study of pelacarsen, a cardiovascular outcomes trial, did not meet its primary endpoint of reducing the risk of cardiovascular events, measured as a composite of cardiovascular death and non-fatal myo…